Shortage of cyclosporine (modified) oral presentations

The American Society of Health-System Pharmacists reports a shortage of cyclosporine (modified) oral presentations. Chemically modified cyclosporine immediately forms an emulsion in water, making it more available to the body. It is more likely to be used to treat psoriasis and rheumatoid arthritis, while unmodified cyclosporine is more likely to be used to prevent rejection of kidney, heart, or liver transplants. Sandoz cites unspecified manufacturing delays as the cause of their shortage. Teva and Watson give no reason for their shortage.